Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 10:2020:2560645.
doi: 10.1155/2020/2560645. eCollection 2020.

Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons

Affiliations
Review

Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons

Rhea Veda Nugraha et al. Evid Based Complement Alternat Med. .

Abstract

Coronavirus disease 2019 (COVID-19) is a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that belongs to the coronavirus family. The first case was reported in December 2019, and the disease has become a pandemic. Impaired immune regulation is one of the factors that play a role in its pathogenesis and results in poor outcomes of COVID-19 patients. There have been many studies with drug candidates used as antivirals or immunomodulators. However, the results of these investigations showed that the drug candidates were not significantly effective against the disease. Meanwhile, people believe that consuming herbal immunomodulators can prevent or even cure COVID-19. Unfortunately, specific preclinical and clinical trials to evaluate the effects of herbal immunoregulators have not been conducted. Certain natural compounds might be effective for the treatment of COVID-19 based on general concepts from previous experiments. This review discusses some herbal agents extracted from various plants, including Echinacea, Cinchona, Curcuma longa, and Curcuma xanthorrhiza, which are considered for the treatment of COVID-19. In addition, we discuss the pros and cons of utilising herbal medicine during the COVID-19 pandemic, draw some conclusions, and make recommendations at the end of the session.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Internalisation process SARS-CoV-2 with its receptor. Red is a spike protein (epitope) of SARS-CoV-2, blue is the ACE2 receptor, and yellow is the serine protease. It shows the internalisation process of this virus into the host cell has occurred (6a and 6b).
Figure 2
Figure 2
Proposed mechanism in which echinacea can enhance the production of IL-1, IL-10, and TNF-α in COVID-19 that can lead to cytokine release syndrome.
Figure 3
Figure 3
Curcumin's role in blood pressure as an antihypertensive agent, ACE inhibitor, and AT1 blocker that can inhibit the AT1 receptor in the renin-angiotensin-aldosterone system (RAAS).
Figure 4
Figure 4
Quinine sulphate has activity as an antiviral agent by enhancing the synthesis of RIG-I and IFN-alpha synthesis. Then, both will block the translation of viral mRNA through the activation of PKR and degrade the viral poly mRNA by activating RNAse (L) Therefore, no viral protein is synthesised.

Similar articles

Cited by

References

    1. Lipsitch M., Swerdlow D. L., Finelli L. Defining the epidemiology of Covid-19-studies needed. New England Journal of Medicine. 2020;382(13):1194–1196. doi: 10.1056/nejmp2002125. - DOI - PubMed
    1. Cheepsattayakorn A., Cheepsattayakorn R. Proximal origin and phylogenetic analysis of COVID-19 (2019-nCoV or SARS-CoV-2) EC Microbiology. 2020;19:9–12.
    1. World Health Organization. Coronavirus Disease 2019. Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Adhikari S. P., Meng S., Wu Y., et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty. 2020;9(29):1–12. doi: 10.1186/s40249-020-00646-x. - DOI - PMC - PubMed
    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. doi: 10.1016/s0140-6736(20)30183-5. - DOI - PMC - PubMed

LinkOut - more resources